Transcutaneous Monitoring of Oxygen and Carbon Dioxide in Surgical Patients

Rigshospitalet

Status: Completed

Conditions: Peripheral Perfusion; Microcirculation; Tissue Metabolism; Transcutaneous Monitoring

Treatments: Device: Transcutaneous monitoring

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04040478

TCM study

Details and patient eligibility

About

The study will investigate if non-invasive continuous transcutaneous blood gas monitoring can detect tissue perfusion and hypoxemia and the relation to other circulatory parameters such as pulse, blood pressure, cardiac output and arterial saturation.

Full description

Macro circulatory parameters such as cardiac output, mean arterial pressure and arterial oxygen saturation are used to monitor the hemodynamic function and tissue perfusion in surgical patients. Though none of the methods are directly monitoring changes in the metabolism of the tissue. Arterial blood gas analysis is used as the golden standard for the detection of metabolic disturbances before, during and after surgery. Disadvantages of the method are 1) the fact that the technique is invasive to the patient, 2) that the method measures the "total gas" (each tissue's contribution to the blood gas in the total circulating blood) and 3) that the methods only provide a snapshot of the patient's blood gas status. Transcutaneous monitoring can be used as a continuous monitoring of the underlying tissue's carbon dioxide and oxygen levels in patients. The method is already used in neonates as a surrogate for the arterial blood gas analysis. Reduced tissue oxygenation due to inadequate perfusion, will initiate an anaerobic tissue metabolism resulting in low oxygen levels and high carbon dioxide levels. The transcutaneous monitoring can therefore potentially be used to detect tissue hypoxia and become a direct measurement of the underlying tissue metabolism.

Enrollment: 30 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients undergoing surgery for abdominal cancer
• patients undergoing femoral endarterectomy

Exclusion criteria

• patients not able to give a informed consent

Trial design

30 participants in 2 patient groups

Abdominal

Description:

80 patients undergoing surgery for abdominal cancer. Data review for interim analysis will be conducted after the participation of 40 patients to evaluate the requirement for further enrollment.

Treatment:

Device: Transcutaneous monitoring

Vascular

Description:

20 patients undergoing femoral endarterectomy.

Treatment:

Device: Transcutaneous monitoring